Literature DB >> 30201549

Color vision impairments in schizophrenia and the role of antipsychotic medication type.

Thiago Monteiro Paiva Fernandes1, Steven M Silverstein2, Pamela D Butler3, Szabolcs Kéri4, Lucas Galdino Santos5, Renata Lyra Nogueira5, Natanael Antonio Santos5.   

Abstract

Schizophrenia patients (SCZ) demonstrate deficits in many domains of mental functioning, including visual perception. An issue that has been relatively unexplored, in terms of explaining variation in visual function in SCZ, however, is medication use. The present study explored potential medication effects on color vision in SCZ, a process that is strongly linked to dopaminergic function in the retina. SCZ patients who had clear-cut either typical (n = 29) or atypical (n = 29) monotherapy, without any other concurrent medication, and a group of age- and gender-matched healthy controls participated in the study. Color vision was assessed by the Cambridge Colour Test, using the Trivector and Ellipse subtests. The results demonstrated impaired color perception in patients with schizophrenia, especially in those receiving typical antipsychotics, but these deficits were subtle and not generalized to all parameters. Our findings are consistent with the known neurophysiology of the retina and visual pathways, and with the effects of dopamine blocking medications, but the results should be carefully interpreted.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Antipsychotics; Cambridge Colour Test; Color vision; Psychiatry; Schizophrenia

Mesh:

Substances:

Year:  2018        PMID: 30201549     DOI: 10.1016/j.schres.2018.09.002

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  8 in total

1.  Spatial contrast sensitivity: effects of reliability, test-retest repeatability and sample size using the Metropsis software.

Authors:  Thiago Paiva Fernandes; Natalia Leandro de Almeida; Pamela D Butler; Natanael Antonio Santos
Journal:  Eye (Lond)       Date:  2019-06-05       Impact factor: 3.775

2.  Chromatic discrimination measures in mature observers depend on the response window.

Authors:  Julien Fars; Thiago P Fernandes; Cord Huchzermeyer; Jan Kremers; Galina V Paramei
Journal:  Sci Rep       Date:  2022-05-31       Impact factor: 4.996

Review 3.  THE USE OF ELECTRORETINOGRAPHY AND OPTICAL COHERENCE TOMOGRAPHY IN PATIENTS WITH SCHIZOPHRENIA.

Authors:  Din Duraković; Ante Silić; Vjekoslav Peitl; Rašeljka Tadić; Kristina Lončarić; Trpimir Glavina; Daniela Šago; Ljiljana Pačić Turk; Dalibor Karlović
Journal:  Acta Clin Croat       Date:  2020-12       Impact factor: 0.932

4.  Irreversible Primary Visual Cortex Impairment in a Mouse Model of High-Risk Schizophrenia.

Authors:  Xinying Chen; Ce Chen; Feng Ji; Yong Xu; Wenqiang Wang; Xiaodong Lin; Deguo Jiang; Xueqin Song; Xiangyang Gao; Hongjun Tian; Chuanjun Zhuo; Jingliang Zhang
Journal:  Neuropsychiatr Dis Treat       Date:  2021-01-29       Impact factor: 2.570

5.  Visual impairment and associated factors among pregnant women attending antenatal care units at health institutions in Gondar City Administration, Northwest Ethiopia.

Authors:  Mengistie Diress; Yitayeh Belsti; Mihret Getnet; Sofonias Addis Fekadu; Baye Dagnew; Yonas Akalu; Mohammed Abdu Seid; Yibeltal Yismaw Gela
Journal:  BMC Pregnancy Childbirth       Date:  2021-12-13       Impact factor: 3.007

6.  Color painting predicts clinical symptoms in chronic schizophrenia patients via deep learning.

Authors:  Hui Shen; Shui-Hua Wang; Yi Zhang; Haixia Wang; Feng Li; Molly V Lucas; Yu-Dong Zhang; Yan Liu; Ti-Fei Yuan
Journal:  BMC Psychiatry       Date:  2021-10-22       Impact factor: 3.630

7.  Association between cognition and color discrimination among Lebanese patients with schizophrenia.

Authors:  Oussama Dahdouh; Tala Solh; Chadia Haddad; Souheil Hallit; Corinne Lahoud
Journal:  BMC Psychiatry       Date:  2022-09-12       Impact factor: 4.144

8.  A case of schizophrenia with congenital color vision deficiency: From the perspective of color universal design to promote medication adherence.

Authors:  Kensuke Miyazaki; Michiko Uchiyama; Chieko Tsushima; Kentarou Fujimoto
Journal:  Neuropsychopharmacol Rep       Date:  2022-06-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.